Literature DB >> 23859571

Impact of pharmacogenetics on CNS side effects related to efavirenz.

Almudena Sánchez Martín1, Salvador Cabrera Figueroa, Raquel Cruz Guerrero, Liliana Porras Hurtado, Alfonso Dominguez-Gil Hurlé, Angel Carracedo Álvarez.   

Abstract

AIM: This article evaluates which genetic factors are involved in CNS toxicity related to long-term treatment with efavirenz (EFV) standard doses and their relationship with plasma concentrations. PATIENTS &
METHODS: A total of 119 HIV-positive patients, in which 1350 EFV plasma concentrations, 68 SNPs and 14 EFV-related adverse effects (AEs) were analyzed.
RESULTS: Overall, 32.77% of patients reported CNS toxicity and 8.40% had concentrations above the therapeutic range. A correlation was mainly found between patients with global CNS AEs and high EFV maximum steady-state plasma concentration (p = 1.47 × 10(-6)). A preliminary analysis confirmed that CYP2B6*6 (516G>T and 785A>G) was the most highly correlated (p = 0.005) with AEs and high plasma concentrations. In a second analysis adjusting for maximum steady-state plasma concentration, suggestive genetic associations were found between BCRP 421C>A, MRP1 816G>A, 5-HT2A 102C>T and different AEs.
CONCLUSION: The finding of the involvement of these SNPs in EFV toxicity opens the door for further studies to confirm their validity and for their application in the future clinical practice. Original submitted 18 February 2013; Revision submitted 17 May 2013.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23859571     DOI: 10.2217/pgs.13.111

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  16 in total

Review 1.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

2.  Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.

Authors:  Eric H Decloedt; Phumla Z Sinxadi; Gert U van Zyl; Lubbe Wiesner; Saye Khoo; John A Joska; David W Haas; Gary Maartens
Journal:  J Antimicrob Chemother       Date:  2019-03-01       Impact factor: 5.790

3.  Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.

Authors:  Jason D Robarge; Ingrid F Metzger; Jessica Lu; Nancy Thong; Todd C Skaar; Zeruesenay Desta; Robert R Bies
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

4.  Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.

Authors:  Paul Curley; Rajith K R Rajoli; Darren M Moss; Neill J Liptrott; Scott Letendre; Andrew Owen; Marco Siccardi
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.

Authors:  Robert Gross; Scarlett L Bellamy; Bakgaki Ratshaa; Xiaoyan Han; Marijana Vujkovic; Richard Aplenc; Andrew P Steenhoff; Mosepele Mosepele; Ganesh Moorthy; Athena F Zuppa; Brian L Strom; Gregory P Bisson
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

Review 6.  PharmGKB summary: Efavirenz pathway, pharmacokinetics.

Authors:  Ellen M McDonagh; Johnathan L Lau; Maria L Alvarellos; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-07       Impact factor: 2.089

7.  CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women.

Authors:  Carola R Röhrich; Britt I Drögemöller; Ogechi Ikediobi; Lize van der Merwe; Nelis Grobbelaar; Galen E B Wright; Nathaniel McGregor; Louise Warnich
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-29       Impact factor: 2.205

Review 8.  Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.

Authors:  Luc Bertrand; Madhavan Nair; Michal Toborek
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 9.  Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.

Authors:  Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar
Journal:  Neurotox Res       Date:  2016-06-30       Impact factor: 3.911

10.  Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.

Authors:  Ahmed M Abdelhady; Tyler Shugg; Nancy Thong; Jessica Bo Li Lu; Yvonne Kreutz; Heather A Jaynes; Jason D Robarge; James E Tisdale; Zeruesenay Desta; Brian R Overholser
Journal:  J Cardiovasc Electrophysiol       Date:  2016-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.